MIRUM PHARMACEUTICALS INC's ticker is MIRM and the CUSIP is 604749101. A total of 103 filers reported holding MIRUM PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.32 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,227,218 | +32.5% | 38,836 | +8.5% | 0.00% | – |
| Q2 2023 | $926,198 | +60.0% | 35,802 | +48.6% | 0.00% | – |
| Q1 2023 | $578,882 | +23.2% | 24,100 | 0.0% | 0.00% | – |
| Q4 2022 | $469,950 | +8.5% | 24,100 | +17.0% | 0.00% | – |
| Q3 2022 | $433,000 | +8.0% | 20,600 | 0.0% | 0.00% | – |
| Q2 2022 | $401,000 | -11.7% | 20,600 | 0.0% | 0.00% | – |
| Q1 2022 | $454,000 | +38.0% | 20,600 | 0.0% | 0.00% | – |
| Q4 2021 | $329,000 | -1.2% | 20,600 | +23.4% | 0.00% | – |
| Q3 2021 | $333,000 | +15.2% | 16,700 | 0.0% | 0.00% | – |
| Q2 2021 | $289,000 | -2.0% | 16,700 | +12.1% | 0.00% | – |
| Q1 2021 | $295,000 | +13.5% | 14,900 | 0.0% | 0.00% | – |
| Q4 2020 | $260,000 | +0.8% | 14,900 | +11.2% | 0.00% | – |
| Q3 2020 | $258,000 | -1.1% | 13,400 | 0.0% | 0.00% | – |
| Q2 2020 | $261,000 | -97.7% | 13,400 | -98.8% | 0.00% | -100.0% |
| Q3 2019 | $11,517,000 | – | 1,144,813 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 6,470,392 | $204,464,387 | 13.58% |
| NEA Management Company, LLC | 2,186,243 | $69,085,279 | 5.34% |
| TANG CAPITAL MANAGEMENT LLC | 1,137,107 | $35,932,581 | 5.07% |
| BOONE CAPITAL MANAGEMENT LLC | 389,791 | $12,317,396 | 3.89% |
| Highlander Partners, L.P. | 122,980 | $3,886,168 | 3.84% |
| BVF INC/IL | 4,370,024 | $138,092,758 | 3.72% |
| Prosight Management, LP | 353,508 | $11,170,853 | 3.54% |
| Novo Holdings A/S | 1,500,000 | $47,400,000 | 3.50% |
| Nicholas Investment Partners, LP | 1,199,366 | $37,899,966 | 2.83% |
| Eventide Asset Management | 3,958,579 | $125,091,097 | 2.25% |